Prohibitions Against Discriminatory Practices Relating to 340B Entities and 340B Drugs
HB 1527 creates a set of state-law protections for participants in the federal 340B Drug Discount Program, which allows certain covered entities to purchase outpatient drugs at reduced prices. The bill defines “340B drug” and “340B entity” and then prohibits drug manufacturers from interfering with a covered entity’s ability to acquire 340B drugs, have them delivered to contracted pharmacies, or contract with pharmacies to dispense them. It also bars manufacturers from using conduct covered by the bill as a basis for unfair trade practice liability under Florida law.
The bill extends similar anti-discrimination rules to health insurance issuers, pharmacy benefit managers, third-party payors, and health maintenance organizations. For prescription drug reimbursement, these entities could not pay 340B entities less solely because a claim involves a 340B drug, impose special fees, clawbacks, audit burdens, claim modifiers, network restrictions, or other conditions not applied to non-340B entities, or require disclosure of ingredient costs or pricing data. The bill also prohibits actions that would interfere with a patient’s ability to obtain drugs from a 340B entity through direct dispensing, delivery, mail order, or administration.
In terms of state-law impact, the bill creates new sections in the Florida Statutes and makes each prohibited act a deceptive and unfair trade practice under the Florida Deceptive and Unfair Trade Practices Act. That means violators would be subject to the investigative demands, remedies, and penalties available under chapter 501. The bill expressly excludes Medicaid reimbursement for covered outpatient drugs from most of these restrictions, and it applies to individual, group, blanket, and franchise health insurance policies as well as HMOs.
The general sentiment reflected by the bill text is strongly supportive of 340B entities and pharmacies that serve them, with the measure framed as a protection against discriminatory reimbursement and contracting practices. Because there were no committee transcripts or recorded votes provided, there is no documented debate in the supplied materials, but the structure of the bill suggests a policy goal of preserving access to discounted drugs and preventing payors and manufacturers from imposing special burdens on 340B participants.
The main point of contention likely centers on whether the bill would limit the ability of insurers, PBMs, and manufacturers to manage drug costs, audit claims, and enforce network or billing rules. Opponents of similar measures often argue that 340B protections can reduce transparency and constrain cost-control tools, while supporters argue that the bill prevents unfair targeting of safety-net providers and their contracted pharmacies. The bill’s broad prohibition on differential treatment, especially around claim modifiers, audits, and reimbursement rates, is likely to be the most disputed aspect.
HB 1527 would add new statutory protections in chapters 499, 626, 627, and 641 of the Florida Statutes, and it would tie violations to the Florida Deceptive and Unfair Trade Practices Act. It would regulate manufacturers, health insurers, pharmacy benefit managers, third-party payors, and HMOs by prohibiting differential reimbursement, special claim-processing requirements, network exclusions, and interference with 340B pharmacy contracting and drug acquisition. The bill would not apply to Medicaid reimbursement for covered outpatient drugs in the same way, and it would take effect July 1, 2025.
The bill appears generally favorable toward 340B covered entities, contracted pharmacies, and patients who rely on them, with the text designed to prevent what it characterizes as discriminatory practices by manufacturers, insurers, and PBMs. No committee discussion or vote history was provided, so there is no recorded legislative debate in the supplied materials. Based on the bill’s framing, the policy sentiment is protective of access and reimbursement parity rather than cost-containment or insurer flexibility.
The likely contention is between 340B hospitals, clinics, and pharmacies that want reimbursement parity and freedom from extra administrative burdens, and manufacturers, insurers, PBMs, and other payors that may view the bill as restricting their ability to manage claims, audit inventory, or apply network and pricing controls. The most disputed provisions are those banning lower reimbursement for 340B claims, prohibiting claim modifiers or attestations, limiting audits, and preventing network exclusion based on 340B participation. The Medicaid carveout may also be a point of focus because it narrows the bill’s reach in one major public payor setting.